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Abstract 
Liver damage and fibrosis are precursors of hepatocellular carcinoma (HCC). In HCC patients, sorafenib—a 
multikinase inhibitor drug—has been reported to exert anti-fibrotic activity. However, incomplete inhibition of 
RAF activity by sorafenib may also induce paradoxical activation of the mitogen-activated protein kinase 
(MAPK) pathway in malignant cells. The consequence of this effect in non-malignant disease (hepatic fibrosis) 
remains unknown. This study aimed to examine the effects of sorafenib on activated hepatic stellate cells 
(HSCs), and develop effective therapeutic approaches to treat liver fibrosis and prevent cancer development. 
Methods: We first examined the effects of sorafenib in combination with MEK inhibitors on fibrosis 
pathogenesis in vitro and in vivo. To improve the bioavailability and absorption by activated HSCs, we developed 
CXCR4-targeted nanoparticles (NPs) to co-deliver sorafenib and a MEK inhibitor to mice with liver damage. 
Results: We found that sorafenib induced MAPK activation in HSCs, and promoted their myofibroblast 
differentiation. Combining sorafenib with a MEK inhibitor suppressed both paradoxical MAPK activation and 
HSC activation in vitro, and alleviated liver fibrosis in a CCl4-induced murine model of liver damage. 
Furthermore, treatment with sorafenib/MEK inhibitor-loaded CXCR4-targeted NPs significantly suppressed 
hepatic fibrosis progression and further prevented fibrosis-associated HCC development and liver metastasis. 
Conclusions: Our results show that combined delivery of sorafenib and a MEK inhibitor via CXCR4-targeted 
NPs can prevent activation of ERK in activated HSCs and has anti-fibrotic effects in the CCl4-induced murine 
model. Targeting HSCs represents a promising strategy to prevent the development and progression of 
fibrosis-associated HCC. 
Key words: CXCR4-targeted nanoparticle; MAPK/ERK pathway; liver fibrosis; hepatocellular carcinoma; liver 
metastasis 
Introduction 
Chronic liver injury results in inflammation, 
angiogenesis and excessive extracellular matrix 
(ECM) deposition, leading to liver fibrosis and 
cirrhosis, liver failure, portal hypertension, and 
development of hepatocellular carcinoma (HCC)[1-3]. 
Around 80-90% of HCC—one of the most common 
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cancers with a high mortality rate—arises in a 
cirrhotic liver [4]. In the clinic, most patients are 
initially diagnosed with advanced fibrosis or 
cirrhosis, which cannot be reversed using existing 
therapies. Thus, anti-fibrosis therapies that aim to 
inhibit disease progression and suppress advanced 
fibrosis and cirrhosis are urgently needed [5-9]. 
Emerging treatments are aimed at inhibiting the 
activation of hepatic stellate cells (HSCs), preventing 
ECM deposition or accelerating the degradation of 
ECM to achieve anti-fibrotic effects [10].  
The discovery and characterization of 
fibrosis-promoting molecules or pathways in HSCs 
have provided new insights into treating liver 
cirrhosis [1, 11, 12]. Small molecule drugs are being 
developed to target activated HSCs to inhibit the 
production of key structural ECM components (e.g., 
collagen I), block fibrogenic signaling pathways, such 
as PDGF/PDGF receptor beta (PDGFRβ), or suppress 
proangiogenic pathways such as VEGF/VEGF 
receptor (VEGFR) axes [5]. Indeed, sorafenib—a drug 
approved and widely used for liver cancer that has 
dual VEGFR/PDGFR inhibitory activity—was shown 
to exert anti-fibrotic activity in preclinical and clinical 
studies [13-18]. Mechanistic studies in experimental 
models of hepatic fibrosis showed that sorafenib 
treatment can decrease ECM deposition, reduce the 
activation of HSCs, and inhibit angiogenesis [19, 20].  
However, two major challenges remain for the 
preventative, chronic use of sorafenib as anti-fibrosis 
treatment in patients. Firstly, as demonstrated in 
cancer studies, RAF kinase inhibitors such as 
sorafenib can induce paradoxical activation of the 
MAPK pathway in both malignant and normal 
stromal cells [21-24]. Activation of MAPK pathway in 
HSCs leads to their activation, but whether this effect 
is induced in activated HSCs during liver damage is 
unknown. Secondly, sorafenib often causes unwanted 
off-target effects, leading to hand-foot syndrome, 
diarrhea, and hypertension, as a result of non-specific 
uptake of the drugs by normal tissues [25]. These 
challenges emphasize the urgent need to determine 
the mechanism of resistance to sorafenib in liver 
fibrosis and to develop safer, more selective 
therapeutic strategies. 
The purpose of this study was to examine the 
effects of sorafenib on activated HSCs, and identify 
molecular targets for developing effective 
combination therapeutic approaches to treat liver 
fibrosis. Furthermore, we sought to develop and test 
HSC-targeted nanoparticles (NPs) for the co-delivery 
of multiple therapeutic cargoes with the aim of 
enhancing anti-fibrotic effects and preventing 
hepatocarcinogenesis. 
Materials and methods 
Cells and materials  
HSCs were purchased from ScienCell Research 
Laboratories (San Diego, CA). Cells were activated 
after they were cultured for 7 days on plastic dishes. 
Sorafenib and Selumetinib (AZD6244) was obtained 
from LC Laboratories (Woburn, MA). For in vivo liver 
metastasis studies, the Pancreatic ductal 
adenocarcinoma (PDAC) cells AK4.4 were stably 
transduced with Gluc/GFP gene by using a retroviral 
vector. Carbon tetrachloride (CCl4), olive oil, 
coumarin 6, dimethyl sulfoxide (DMSO), 
D-α-Tocopherol polyethylene glycol 1000 succinate 
(TPGS) and paraformaldehyde were purchased from 
Sigma-Aldrich (St, Louis, MO). 1,2-dioleoyl-sn- 
glycero-3-phosphocholine (DOPC) and 1,2-distearoyl- 
sn-glycero-3-phosphoethanolamine-N-[maleimide(po
lyethylene glycol)-2000] (DSPE-PEG-Maleimide) were 
obtained from Avanti Polar Lipids (Alabaster, AL). 
poly(lactic-co-glycolic acid) (PLGA) (50/50, inherent 
viscosity: 0.17 dL/g) was ordered from Green Square 
Materials Incorporation (Taoyuan, Taiwan). 
Tris(2-carboxyethyl)phosphine (TCEP) disulfide 
reducing gels were purchased from Thermo Fisher. 
CTCE9908 peptide (sequence: Lys-Gly-Val-Ser-Leu- 
Ser-Tyr-Arg-Cys-Arg-Tyr-Ser-Leu-Ser-Val-Gly-Lys) 
and scramble peptide (Leu-Tyr-Ser-Val-Lys-Arg- 
Ser-Gly-Cys-Gly-Ser-Arg-Lys-Val-Ser-Tyr-Leu) were 
synthesized by Kelowna International Scientific 
Incorporation. 
In vivo liver damage models 
C3H/HeNCrNarl male mice (5 weeks) were 
purchased from the National Laboratory Animal 
Center (Taipei, Taiwan). All animals received humane 
care in compliance with the “Guide for the Care and 
Use of Laboratory Animals” published by the 
National Academy of Sciences, and all study 
procedures and protocols (animal ethic number 10457) 
were approved by the Animal Research Committee of 
National Tsing-Hua University. To induce liver 
fibrosis, the mice were treated with 16% (V/V) CCl4 in 
olive oil (2 mL/kg, p.o.) 3 times per week for 8 
continuous weeks. 
To evaluate the anti-fibrotic effect of the drug 
cocktail loaded in the NP formulations, sorafenib or 
AZD6244 (total daily dose: 5 mg/kg, two doses per 
week), loaded in the different formulations, was 
intravenously administered to mice with 
CCl4-induced liver fibrosis beginning 4 weeks after 
the start of CCl4 administration. The changes in 
hepatic fibrosis and vascularization were evaluated 
after 4 weeks of treatment (Fig. 4A). The 
microvascular density (MVD) was quantified by 
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highlighting the blood vessels with Von Willebrand 
factor (vWF)—an endothelial cell marker—using the 
immunohistochemical protocols.  
NPs formulation 
Nanoparticles were synthesized through a 
single-step nanoprecipitation method. PLGA (0.75 
mg), DSPE-PEG-Maleimide (0.0846 mg), sorafenib 
(0.075 mg), AZD6244 (0.075 mg), TPGS (0.375 mg), 
and DOPC (0.0375 mg) were dissolved in 40 μL of 
DMSO as an organic phase. Cholesterol (0.0375 mg) 
was dissolved in alcohol. The organic phase mixture 
was added into 280 μL of deionized water drop wise. 
The formulations were formed with continuous 
stirring for 30 minutes. The ratio of the volumes of the 
oil and water phases was fixed at 1/7 (v/v) 
throughout all experiments. CTCE9908 peptides were 
reduced in a TCEP gel and then incubated with the 
nanoparticle formulations. DSPE-PEG-Maleimide was 
reacted with sulfhydryl groups in CTCE9908 peptides 
to form stable thioether bonds. Four hours after 
incubation, excess maleimides were quenched at the 
end of the reaction by adding free cysteine. To collect 
the peptide-modified NPs, the solution was 
centrifuged at 25,000 rcf for 30 min at 25 °C and 
re-suspended in PBS at the desired concentration for 
further study. Coumarin 6-loaded NPs were 
synthesized following the same procedure with a final 
weight ratio of coumarin 6 to PLGA of 1/150. 
Characterization of NPs 
The particle size and surface charge of the NPs 
were examined at room temperature by a zetasizer 
(300HS, Malvern Instruments Ltd., Worcestershire, 
UK). Transmission electron microscopy (TEM; 
H-7500, Hitachi High-Tech, Tokyo, Japan) was used to 
examine the size and morphology of the NPs. NPs 
were dropped on dried formvar-coated 100-mesh 
copper grids at room temperature and dried for two 
days prior to imaging.  
To measure the encapsulation efficacy, the 
concentrations of sorafenib and AZD6244 were 
analyzed with a UV spectrophotometer (Multiskan, 
Thermo Scientific, Rockford, IL) at 270 nm and 260 
nm, respectively.  
Results 
ERK activation after sorafenib treatment 
mediates HSC activation and survival. 
Treatment of HSCs with sorafenib at 
sub-micromolar concentrations increased phospo- 
extracellular signal–regulated kinases (ERK) levels in 
these cells, whereas pAKT remained strongly 
suppressed due to PDFGR inhibition by sorafenib 
(Fig. 1A and Fig. S1). Moreover, low-dose sorafenib 
promoted the myofibroblast differentiation of HSCs, 
as indicated by the increased expression of α-SMA 
(Fig. 1A). Thus, we next determined whether MAPK 
activation mediated HSC differentiation. As shown in 
Fig. 1B, treatment with MEK inhibitor AZD6244 alone 
only showed moderate suppression of HSC 
activation. However, MEK inhibitor AZD6244 in 
combination with sorafenib synergistically inhibited 
HSC differentiation (decreased expression of α-SMA) 
and activation (reduced expression of collagen I). 
Preventing ERK activation also resulted in reduced 
activation of nuclear factor kappa B (NF-κB) pathway, 
known to promote inflammation in the fibrotic liver 
microenvironment, regulate HSC activation and 
ensure the survival of activated HSCs (Fig. 1B-C). 
Indeed, AZD6244 sensitized HSCs to sorafenib 
treatment, and significantly enhanced the 
pro-apoptotic effects of sorafenib in HSCs (Fig. 1D-E). 
Delivery of CXCR4-targeted NPs containing 
sorafenib and MEK inhibitor to activated HSCs 
suppresses their activation and viability in vitro. 
CXCR4 is a chemokine receptor induced in 
activated HSCs by various cellular stresses during the 
progression of liver fibrosis [16, 26, 27]. Thus, we 
developed CXCR4-targeted NPs to more selectively 
target activated HSCs in fibrotic livers [27]. In this 
study, to improve safety and efficacy of the drug 
cocktail, we co-formulated sorafenib and AZD6244 in 
CXCR4-targeted lipid-coated PLGA NPs modified 
with CTCE9908, a CXCR4 antagonist peptide. 
Electron microscopy imaging of drug-loaded NPs 
showed spherical morphology with an average 
diameter of 140 nm and a polydispersity index (PDI) 
of 0.4, as measured by zetasizer (Fig. 2A). The 
encapsulation efficacy of the drug cocktail in the 
CXCR4-targeted PLGA NPs was ~70%. We first 
examined whether the peptide modification 
(CTCE9908) enhanced the intracellular uptake of NPs 
in activated HSCs. Using coumarin 6 as a tracer 
molecule loaded in NPs, we found that the uptake of 
NPs modified with CTCE9908 (CTCE9908-NPs) was 
significantly enhanced in activated HSCs compared 
with non-targeted NPs conjugated with scramble 
peptides (control-NPs) (Fig. 2B-D). The addition of 
free CTCE9908 peptides reduced the uptake of 
CXCR4-targeted NPs into activated HSCs in a 
dose-dependent manner (Fig. 2E and Fig. S2), 
indicating that the nanoparticle uptake was mediated 
by the CXCR4 antagonist peptide (CTCE9908). 
Furthermore, sorafenib and the MEK inhibitor 
AZD6244 co-formulated in CTCE9908-NPs exerted 
greater cytotoxicity on activated HSCs compared with 
the drug cocktail in the non-targeted NPs 
(control-NPs) or the single agent (sorafenib or 
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AZD6244) delivered by CTCE9908-NPs (Fig. 2F). 
Moreover, sorafenib and AZD6244 co-delivered by 
CTCE9908-NPs prevented the paradoxical activation 
of ERK in HSCs and suppressed HSC differentiation 
and activation, as indicated by the reduced α-SMA 
and collagen I expression (Fig. 2G).  
Systemic treatment with CXCR4-targeted 
NPs containing sorafenib and AZD6244 
reduces liver fibrosis in mice with 
CCl4-induced liver damage. 
We further evaluated in vivo whether 
CTCE9908-NPs exhibited enhanced liver uptake in 
CCl4-treated mice. Coumarin 6 was used as a tracer 
molecule to study the biodistribution of drug-loaded 
NPs in mice with CCl4-induced liver fibrosis 4 h after 
intravenous (I.V.). injection. As shown in Fig. 3A, 
there was an increased uptake of CTCE9908-NPs 
compared to free drug or non-targeted control-NPs in 
the fibrotic livers of CCl4-treated mice. Similar to the 
in vitro results, there was increased intracellular 
uptake of the NPs in the fibrotic livers, indicating that 
the CXCR4 antagonist peptide CTCE9908 can act as a 
targeting moiety for specific delivery in this context 
(Fig. 3B). Next, we examined the anti-fibrotic effects 
of sorafenib and MEK inhibitors co-formulated into 
CXCR4-targeted NPs in CCl4-treated mice. Sorafenib 
or the MEK inhibitor AZD6244, loaded in different 
formulations, were intravenously given to mice with 
CCl4-induced liver fibrosis (5 mg/kg, 2 doses per 
week) starting at the 4th week after the first 
administration of CCl4, and alterations in hepatic 
fibrosis were evaluated after 4 weeks of treatment 
(Fig. 4A). When delivered using CTCE9908-NPs, 
sorafenib and AZD6244 significantly suppressed the 
activation of ERK triggered by sorafenib alone and 
alleviated liver inflammation and fibrosis, as 
measured by quantitative PCR, Masson's trichrome 
and immunohistochemistry (IHC) for collagen I and 
III (Fig. 4B-E and Fig. S3- Fig. S5). The infiltration of 
α-SMA-positive myofibroblasts in the fibrotic liver 
tissue was also significantly reduced in mice treated 
with the combination therapy delivered by 
CTCE9908-NPs compared to single drug (sorafenib or 
 
Fig. 1. Low doses of sorafenib triggered paradoxical activation of ERK and induced HSC activation. A, Low doses of sorafenib increased ERK activation and the expression of 
α-SMA in HSCs. Downregulation of AKT activity was observed after sorafenib treatment. B, The effect of MEK inhibition on HSC activation. MEK inhibition with AZD6244 (2 µM) decreased 
p-IkB-α and α-SMA expression and collagen content in HSCs treated with sorafenib. C, NF-κB luciferase activity from HSCs transfected with NF-κB luciferase construct. Sorafenib caused 
a significant increase in NF-κB activity. MEK inhibition with AZD6244 (1 µM) reversed the effect of sorafenib on NF-κB activation in HSCs (n=8-12). D, Effect of MEK inhibition on cell 
sensitivity to sorafenib. Inhibition of MEK activity with AZD6244 renders HSCs sensitive to sorafenib. E, Combination of sorafenib with MEK inhibitors increases apoptosis in HSCs (n=3-5). 
The data are given as the mean values ± S.E.M., *p<0.05 and **p<0.01. 
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AZD6244 alone) loaded in CTCE9908-NPs (Fig. 4D-F 
and S3-S6). In addition, AST and ALT level 
significantly increased in CCl4-treated mice compared 
with normal control mice, indicating liver damage in 
CCl4-induced liver fibrosis. Sorafenib and AZD6244 
co-delivered by CTCE9908-NPs reduced elevated 
ALT and AST, indicating that the combination 
treatment may facilitate liver repair (Fig. S7). 
Compared with the free-form drug cocktail, the 
CXCR4-targeted NP formulations were more effective 
at a lower dose (5 mg/kg) and dose-dependent 
inhibition of liver fibrosis was observed in mice 
treated with the drug cocktail loaded in the 
CXCR4-targeted NPs (Fig. 4D-G and Fig. S5-S6). 
 
 
Fig. 2. The NPs modified with CTCE9908 peptides showed enhanced cellular uptake in activated HSCs and suppressed HSC viability and activation when loaded with 
sorafenib and the MEK inhibitor AZD6244. A, Structures proposed for the CTCE9908-NPs with a representative TEM image (scale bar=100 nm). B, HSCs were treated with coumarin 
6-loaded NPs modified with CTCE9908 peptides (CTCE9908-NPs) or scramble peptides (control-NPs) at various ratios of DSPE-PEG/peptides for 4 h (scale bar=50 μm). green, coumarin 
6-loaded NPs; blue, DAPI. C-D, The cellular uptake of NPs was imaged and quantified using a Zeiss LSM 780 confocal microscope (n=7). E, The uptake of CTCE9908-NPs in HSCs was 
competitively inhibited by the addition of free CTCE9908 peptides in a dose-dependent manner. Cells were treated with free peptides prior to CTCE9908-NPs and analyzed for fluorescence 
signals by confocal microscopy (n=5-6). F, The cytotoxicity of sorafenib or AZD6244 in different formulations on HSCs was measured using the MTT assay (n=5-6). G, CTCE9908-NPs 
co-delivering sorafenib and AZD6244 prevented the effect of sorafenib on paradoxical activation of ERK and downregulated the expression of collagen I and α-SMA in HSCs. Free drug (AS), 
free-form AZD6244 and sorafenib; control-NP (–), empty NPs modified with scramble peptides; CTCE9908-NPs (–), empty NPs modified with CTCE9908 peptides; CTCE9908-NPs (A), 
CTCE9908-NPs loaded with AZD6244; CTCE9908-NPs (S), CTCE9908-NPs loaded with sorafenib; control-NPs (AS), AZD6244 and sorafenib loaded in NPs modified with scramble 
peptides. The data are given as the mean values ± S.E.M., **p<0.01 and ***p<0.001. 
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Figure 3. The NPs modified with CTCE9908 peptides enhanced coumarin 6 tissue 
uptake in the fibrotic livers of CCl4-treated mice. A, The tissue distribution of coumarin 6 in 
different formulations (n=7-8). Coumarin 6-loaded CTCE9908-NPs showed enhanced tissue uptake 
in the fibrotic livers 4 h after I.V. administration. B, Representative confocal images of the uptake of 
coumarin 6 in different formulations by the fibrotic livers. Green, coumarin 6-loaded NPs; blue, 
DAPI. Scale bar=100 μm. The data are given as the mean values ± S.E.M., *p<0.05 and ***p<0.001. 
 
Figure. 4. Sorafenib and the MEK inhibitor AZD6244 co-formulated in CTCE9908-NPs decrease liver fibrosis and suppress angiogenesis in the CCl4-induced mouse 
model of liver fibrosis. A, Treatment schedule of sorafenib and AZD6244 loaded in different formulations in the CCl4-induced murine model of liver damage. B, Western blot analysis 
showed co-delivery of sorafenib and AZD6244 suppressed ERK activation induced by sorafenib in the fibrotic livers of CCl4-treated mice. C, Sorafenib and AZD6244 loaded in 
CXCR4-targeted NPs inhibited mRNA expression of inflammatory and fibrotic markers such as TNF-α, IL-1b, IL-6, ACTA2, PPARγ, Col1A1 (normalized by β-actin). D, Sorafenib and 
AZD6244 delivered by CTCE9908-NPs (5 mg/kg, I.V., two doses per week) significantly ameliorated liver fibrosis in CCl4-treated mice, as indicated by Masson’s trichrome and IF staining for 
collagen I, α-SMA and von Willebrand factor (vWF) (scale bar=100 μm) (n=5-15). E-F, Quantification of collagen I (E) and α-SMA (F) expression in randomly selected fields within the fibrotic 
livers (n=9-16). G, Sorafenib and AZD6244 loaded in different formulations reduced liver fibrosis in a dose-dependent manner, as indicated by a decrease in collagen I deposition in the fibrotic 
livers (n=5-16). The data are presented as mean values ± S.E.M., **p<0.01 and ***p<0.001.  
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Figure 5. Sorafenib and the MEK inhibitor AZD6244 co-formulated in CTCE9908-NPs suppress angiogenesis in the fibrotic livers of CCl4-treated mice. A, 
Representative confocal images of vWF staining in the fibrotic livers from mice treated with different formulations (scale bar=100 μm). B-C, Sorafenib and AZD6244, delivered by 
CTCE9908-NPs, significantly reduced the microvascular density (B) and decreased the mean vessel diameter (C) in fibrotic livers from CCl4-treated mice, as observed by staining for vWF 
(n=10-26). The data are presented as mean values ± S.E.M., **p<0.01 and ***p<0.001.  
 
Co-delivery of sorafenib and AZD6244 by 
CXCR4-targeted NPs inhibited angiogenesis 
and normalized the vessel morphology in the 
fibrotic livers of CCl4-treated mice. 
Given that sorafenib treatment could attenuate 
liver fibrosis and was associated with the inhibition of 
angiogenesis, we further examined the 
anti-angiogenic activity of sorafenib and AZD6244 
co-formulated in CTCE9908-NPs in mice with 
CCl4-induced liver fibrosis. The MVD in fibrotic livers 
was significantly reduced in mice treated with 
sorafenib and MEK inhibitors co-delivered by 
CTCE9980-NPs compared with mice treated with the 
single drug alone in CTCE9908-NPs or the drug 
cocktail in the non-targeted control-NPs (Fig. 5A-B). 
Furthermore, as shown by the decreased mean vessel 
diameters, sorafenib and AZD6244 loaded in 
CTCE9908-NPs normalized the distorted morphology 
and size of vasculature in the fibrotic livers of mice 
with CCl4-induced liver fibrosis (Fig. 5A, C). 
Sorafenib and MEK inhibitors, which were 
co-formulated in the targeted NPs, suppressed 
angiogenesis in the fibrotic livers of CCl4-treated mice. 
Co-delivery of sorafenib and AZD6244 by 
CXCR4-targeted NPs prevented spontaneous 
HCC development in the fibrotic livers and 
inhibited liver metastasis.  
Progression of liver fibrosis increases the risk of 
HCC development, fuels HCC growth and influences 
treatment prognosis [28-31]. We next evaluated the 
effect of combined sorafenib and AZD6244 in a cancer 
prevention setting when delivered by 
CXCR4-targeted NPs systemically to mice with DEN 
and CCl4-induced liver fibrosis and 
inflammation-associated HCC (Fig. 6A). Sorafenib 
and AZD6244 loaded in CXCR4-targeted NPs 
significantly reduced tumor formation in the fibrotic 
liver as determined by significantly lower liver 
nodules and tumor size associated with reduced 
desmoplasia compared with untreated controls (Fig. 
6B-D). For the combined treatment group, tumor 
incidence was 0.2 (95% confidence interval (CI): 0.05 
and 0.80); for the control group, tumor incidence was 
1.5 (95% CI: 0.95, 2.29). Tumor incidence in the 
combined treatment group was on average 7.3-fold 
(SD ± 2.1) lower than it in the control group. The 
tumor incidence rate was 20% in the sorafenib plus 
AZD6244 group (95% CI: 5.7%, 57.0%), and 80% in the 
control group (95% CI: 49.0%, 94.0%), with a 
difference in incidence rate of 60% (95% CI: 22.4%, 
97.6%, p-value = 0.0035 by normal approximation 
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z-test) (Fig. 6E). Histopathology confirmed a 
significant reduction of tumor lesions in livers treated 
with sorafenib and AZD6244 loaded in 
CXCR4-targeted NPs compared to the untreated 
controls (Fig. 6F-G and S8).  
 
 
Figure 6. Sorafenib and the MEK inhibitor AZD6244 co-formulated in CTCE9908-NPs prevent spontaneous HCC development and PDAC liver metastasis. A, 
Experimental setup. B, Representative livers in a CCl4-induced spontaneous HCC model with or without treatment of sorafenib and AZD6244 loaded in CXCR4-targeted NPs. C-E, Liver 
tumor nodule counts (>1 mm) per mouse (C), maximal tumor sizes (mean ± S.E.M.) (D) and HCC incidence (E) in NP-treated or control mice (n=10). To investigate the number of tumor 
counts emerged in two groups, the generalized linear model of Poisson regression was applied. F, Histopathological analysis of livers in a CCl4-induced spontaneous HCC model with or 
without treatment of Sorafenib and AZD6244 loaded in CXCR4-targeted NPs (green, collagen I; blue, DAPI). Scale bar = 50 µm. G, Quantification of collagen I expression in randomly selected 
fields within the fibrotic livers. H, Mice were inoculated with 2x105 AK4.4 cells into the pancreas. The treatment schedule of established tumors is shown. I, Primary PDAC tumor size after 
treatment. J, Number of metastatic lesions was enumerated in the livers (n=6-10). K, Histopathological analysis of livers in a syngeneic orthotopic PDAC murine model with or without 
treatment of sorafenib and AZD6244 loaded in CXCR4-targeted NPs (red, anti-GFP; green, α-SMA; blue, DAPI). Scale bar = 50 µm. L, Quantification of α-SMA+ myofibroblast infiltration in 
randomly selected fields within livers of syngeneic orthotopic PDAC murine models (n=5). *p<0.05, **p<0.01 and ***p<0.001.  
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Table. 1. Toxicity profile of sorafenib and 
AZD6244-loaded CTCE9908-NPs. Sera of C3H mice were 
collected 24 h after I.V. injections of sorafenib and 
AZD6244-loaded CTCE9908-NPs (5 mg/kg) for evaluation of 
markers for acute kidney injury and liver damage (n=4). 
Abbreviations: ALT: alanine aminotransferase; AST: aspartate 
aminotransferase; ALP: alkaline phosphatase; γ-GT: 
γ-Glutamyltransferase; BUN: Blood urea nitrogen; CREA: 
creatinine. Data are shown as mean values ± S.E.M.. 
Group AST  
(U/L) 
ALT  
(U/L) 
ALP  
(U/L) 
γ-GT  
(U/L) 
BUM 
(mg/dL) 
CREA 
(mg/dL) 
Control 73.2±5.4 31.7±4.5 492.4±50.8 0.1±0.1 33.6±1.0 0.4±0.0 
CTCE9908-NP 
(AS) 
72.1±8.7 27.7±1.7 429.1±35.1 0.0±0.1 33.7±1.4 0.4±0.0 
n=4-6 
 
 
In addition to primary cancer formation, the 
activation of HSCs by tumor-derived soluble factors 
or extracellular vesicles in the liver microenvironment 
plays a critical role in the development of liver 
metastasis [32, 33]. We examined the effect of 
sorafenib and AZD6244 loaded in HSC-targeted NPs 
on the incidence of liver metastasis in mice. A 
spontaneous liver metastasis model was established 
by the inoculation of PDAC cells into pancreas of 
6-8-week-old FVB mice (Fig. 6H). The treatment 
began on day 9 after inoculation with 2x105 AK4.4 
(GFP/GLuc) cells orthotopically in mice (Fig. 6H). 
Mice inoculated with orthotopic PDAC developed 
metastatic tumor lesions in livers with increased 
infiltration of α-SMA-positive myofibroblasts and 
F4/80+ macrophages (Fig. 6I-L). In contrast, systemic 
administration of sorafenib and AZD6244 (5 mg/kg) 
loaded in CXCR4-targeted NPs on days 9, 12, 15 and 
18 reduced the infiltration of α-SMA-positive 
myofibroblasts and F4/80+ macrophages, deceased 
collagen deposition in livers and suppressed the 
incidence of liver metastasis (Fig. 6I-L and Fig. 
S9-S10), without affecting the primary PDAC tumor 
burden (Fig. 6I). Moreover, the safety study showed 
that the serum levels of hepatotoxicity makers and 
kidney injury markers remained unchanged after 
treatment with sorafenib and MEK inhibitors in 
CTCE9908-NPs (Table 1).  
Discussion 
Liver fibrosis is driven by abnormal activation of 
various signaling pathways, including MAPK, in 
HSCs, leading to their myofibroblast differentiation 
and activation, and abnormal angiogenesis. Sorafenib, 
a multikinase inhibitor that targets RAF/MEK/ERK 
pathway and PDGFR/VEGFR suppresses 
proliferation and activation of HSCs and angiogenesis 
and thus opens the possibility of using this drug to 
treat liver fibrosis and prevent HCC. However, 
previous studies from our group and others have 
demonstrated that RAF inhibitors such as sorafenib 
paradoxically induce MAPK activation in cancer cells, 
leading to treatment resistance [24]. These studies 
highlighted the potential therapeutic benefit of 
combining sorafenib and MEK inhibitors for treating 
hepatic malignancies. In this study, we further show 
here that low doses of sorafenib can induce 
paradoxical activation of ERK in HSCs. In turn, this 
leads to HSC activation reflected by enhanced 
collagen I production. NF-κB activation in HSCs also 
plays a crucial role in the progression of hepatic 
fibrosis by promoting HSC activation and 
proliferation, inhibiting apoptosis and increasing the 
secretion of chemokines and recruitment of 
inflammatory cells (e.g., macrophages) [30]. Although 
sorafenib blocking of RAF and PDGFR has potential 
anti-fibrotic/anti-inflammatory properties, 
treatment-induced ERK and NF-κB activation in 
HSCs can limit its therapeutic activity. Indeed, 
sorafenib alone only moderately attenuated hepatic 
fibrosis in vivo. Combining sorafenib with a MEK 
inhibitor (AZD6244) can prevent MAPK and NF-κB 
activation in HSCs and achieve synergistic 
anti-fibrotic efficacy. A similar effect on inhibition of 
HSC activation was observed after treatment of MEK 
inhibitor in combination with a selective PDGFR 
blockade (Fig. S1). Profound anti-fibrotic effects may 
only be achieved through targeting multiple 
pro-fibrotic pathways. This combination approach 
may have impact beyond alleviation of liver fibrosis. 
HSC activation also serves a key element in the 
creation of a pro-tumor microenvironment. Thus, the 
combination of sorafenib with MEK inhibitors may 
potentially have beneficial effects on both controlling 
fibrosis and preventing progression of malignant 
disease.  
HCC is a complex disease associated with 
multiple risk factors and underlying conditions such 
as alcoholic liver disease, viral hepatitis and 
nonalcoholic fatty-liver disease. HCC mostly arises in 
the setting of cirrhosis resulting from repeated liver 
damage and chronic inflammation. To model the 
clinical feature of HCC with underlying liver 
cirrhosis, DEN was first administrated to trigger DNA 
damage and develop a mutagenic environment in 
liver tissues. Following administration of DEN, severe 
fibrotic liver damage and HCC formation were 
induced by repeated exposure to CCl4 [34]. Sorafenib 
and AZD6244 co-formulated in CXCR4-targeted NPs 
reduced desmoplasia and attenuated HCC formation 
in this clinically relevant model in the setting of 
carcinogenesis within cirrhotic liver tissues. However, 
about 15%-20% of HCC develop in the non-fibrotic or 
minimal fibrotic livers. For example, NASH/NAFLD- 
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associated HCC may also derive from noncirrhotic 
livers in the setting of steatosis with inflammation 
[35]. In this study, we demonstrated the reduced 
expression of pro-inflammatory cytokines in livers 
after treatment with combined sorafenib and 
AZD6244. Given the anti-inflammatory properties of 
the drug cocktail, combined sorafenib and AZD6244 
may also serve as an effective therapeutic strategy for 
liver diseases with an underlying pro-inflammatory 
microenvironment. Our previous finding showed 
sorafenib in combination of AZD6244 synergistically 
suppressed the orthotopic HCC progression without 
underlying cirrhosis [24]. Taken together, 
combination therapy with sorafenib and MEK 
inhibitors has potential as a preventive and 
therapeutic agent for multiple liver diseases, 
including liver cancer. 
The fibrotic microenvironment not only 
promotes primary liver formation, but also sustains 
metastatic tumor growth in livers. Interestingly, we 
observed enhanced PDAC metastatic development in 
CCl4-induced fibrotic livers compared with normal 
livers. On the other hand, during the progression of 
PDAC, soluble factors or extracellular vesicles 
released from metastasis-associated macrophages 
(MAMs) or tumor cells activate HSCs and develop the 
fibrotic microenvironment that promotes the 
metastatic seeding of tumor cells. Treatment of 
sorafenib and AZD6244 loaded in CXCR4-targeted 
NPs reduced HSC activation and macrophage 
infiltration, leading to the suppression of liver 
metastatic incidence. These findings indicate that 
targeting the pro-fibrotic niche may serve as a 
potential therapeutic approach to treating PDAC liver 
metastasis. 
In preclinical studies of HCC, MEK inhibition 
enhanced the anti-cancer efficacy of sorafenib [24, 36]. 
These agents have also been tested in phase II clinical 
trials in advanced HCC patients, with promising 
activity but frequent dose reductions due to adverse 
effects [37]. Side effects, including rash, fatigue, 
edema, gastrointestinal symptoms, neurological 
symptoms, and liver function impairment, are often 
observed in patients treated with kinase inhibitors 
[38]. Thus, translating this combination for treatment 
of liver disease in cancer prevention settings raises 
significant toxicity concerns. To address this issue, we 
developed a nano-carrier that was modified with a 
peptide targeting CXCR4 to co-deliver sorafenib and 
MEK inhibitors, and improve their bioavailability and 
absorption by activated HSCs in fibrotic livers. The 
PLGA NPs that had slow-release properties 
significantly extended the blood circulation of the 
cargo and enhanced drug accumulation in the fibrotic 
livers [39]. We further modified the PLGA NPs with 
peptides targeting CXCR4 to achieve ligand-mediated 
targeting to HSCs wherein CXCR4 expression was 
upregulated in response to activation [40]. Sorafenib 
and MEK inhibitors co-delivered by the 
CXCR4-targeted NPs prevented MAPK activation, 
suppressed hepatic fibrosis progression and 
attenuated angiogenesis in the fibrotic livers of 
CCl4-treated mice with no apparent toxicity. Our 
results demonstrate that a cocktail of sorafenib and 
MEK inhibitors loaded in the targeted drug carriers is 
a safe and promising therapeutic strategy for liver 
fibrosis.  
In summary, we showed that combining 
sorafenib with MEK inhibition is efficacious in 
reducing CCl4-induced liver fibrosis in mice. 
Moreover, combining sorafenib and MEK 
inhibitor-loaded NPs for more selective targeting of 
activated HSCs was safe and achieved significant 
anti-fibrotic effects and inhibited primary HCC 
formation and metastatic dissemination of PDAC to 
the fibrotic liver (Fig. 7). This novel therapeutic 
strategy should be further tested in models of liver 
fibrosis and for preventing malignant transformation 
and progression in the liver. 
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Fig. 7. Schematic illustration of the mechanisms by which sorafenib and AZD6244-loaded CTCE9908-NPs ameliorated liver fibrosis. Sorafenib paradoxically activates ERK 
and increases the activation of NF-κB expression, which increases α-SMA expression and the production of collagen in HSCs. Sorafenib and the MEK inhibitor AZD6244, when co-formulated 
in CTCE9908-NPs, suppressed ERK activation and inhibited HSC activation, enhancing the anti-fibrotic and cancer prevention effect in a murine model of liver damage. 
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